Rabusertib
Rabusertib (LY2603618) is a potent and selective inhibitor of Chk1 with an IC50 of 7 nM.
Product Specifications
CAS Number
[911222-45-2]
Product Name Alternative
LY2603618; IC-83
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Autophagy; Checkpoint Kinase (Chk)
Type
Reference compound
Related Pathways
Autophagy; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LY2603618.html
Concentration
10mM
Purity
99.98
Solubility
DMSO : 31.25 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
BrC(C=C1NC(NC2=NC=C(N=C2)C)=O)=C(C=C1OC[C@H]3OCCNC3)C
Molecular Formula
C18H22BrN5O3
Molecular Weight
436.30
Precautions
H302, H315, H319, H335
References & Citations
[1]King C, et al. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor. Invest New Drugs. 2014 Apr;32 (2) :213-26.|[2]Wang G, et al. Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One. 2013 Sep 30;8 (9) :e76662.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
Chk1; Chk2
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
124285-FITC 100 µL
CAMK2A (Calcium/Calmodulin-dependent Protein Kinase Type II Subunit alpha, CaM-kinase II Subunit alpha, CaM Kinase II Subunit alpha, CAMKA, KIAA0968) (FITC)
Ask
View Details 
